# Administrative Core A

> **NIH NIH U19** · OREGON HEALTH & SCIENCE UNIVERSITY · 2020 · $141,355

## Abstract

Core A (Administration) Summary 
The purpose of Core A (Administrative Core) is to provide the organizational framework to optimally implement 
an Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) Program to design and develop an 
efficacious HIV/AIDS prophylactic vaccine based on Cytomegalovirus (CMV) vectors. This framework will 
provide scientific leadership and integration of the Program, as well as administrative support and assistance 
to the Program Director and Project Leaders. This includes providing logistical support on administrative and 
clerical matters, facilitating interactions between Project and Core Leaders and providing a forum for decision 
making, database maintenance and administration, data sharing, experimental planning, manuscript writing 
and submission, progress report submission, and financial tracking and management, as well as organizing an 
external advisory committee (EAC) to evaluate the progress and overall direction of the program. 
The specific aims of this Core are: 
1. To ensure an interactive environment and foster a cohesive, focused relationship among Program 
 scientists and to provide a forum for Project and Core Leaders to set overall priorities and make key 
 decisions via regular meetings and videoconferences. 
2. To promote scientific advancement of the Program by establishing an external advisory committee (EAC) 
 to review the progress of the program, and provide independent scientific and clinical development 
oversight. 
3. To provide fiscal oversight and general administrative, budgetary, database, and statistical support for the 
 overall program, 
4. To maintain communication with the NIAID program officer and other NIAID staff, coordinate reports to the 
 NIH and EAC and ensure compliance with NIH and local institutional requirements. 
5. To coordinate clinical development with our commercial partner TomegaVax, and plan and obtain funding 
 for a Phase 1 clinical trial of the 2nd generation HCMV/HIV vector product designed and manufactured in 
 this program.

## Key facts

- **NIH application ID:** 9883701
- **Project number:** 5U19AI128741-04
- **Recipient organization:** OREGON HEALTH & SCIENCE UNIVERSITY
- **Principal Investigator:** Louis J. Picker
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $141,355
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9883701

## Citation

> US National Institutes of Health, RePORTER application 9883701, Administrative Core A (5U19AI128741-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9883701. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*